Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Convalescent plasma is a biological therapy derived from the blood of individuals who have recovered from a specific infection, such as COVID-19. This plasma contains neutralizing antibodies (immunoglobulins) generated by the donor's immune system that can target and neutralize the causative pathogen, in this case, the SARS-CoV-2 virus. The Hospital Universitario Dr. Jose E. Gonzalez initiated a Phase 2 clinical trial to evaluate the efficacy and safety of this therapy in patients with SARS-CoV-2 pneumonia, comparing it to the best available therapy to determine its impact on mortality and clinical recovery. The treatment involves the intravenous administration of fractionated plasma aliquots to provide passive immunity to infected subjects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on convalescent plasma (Hospital Universitario Dr. Jose E. Gonzalez).